Burjeel’s $750m IPO plan led to AED 10.4bn ADX hospital benchmark

Burjeel Holdings turned a reported $750 million IPO plan on 4 August 2022 into an Abu Dhabi Securities Exchange (ADX) listing that raised more than AED 1.1 billion and valued the hospital group at AED 10.4 billion.

For healthcare CEOs, CFOs and corporate development teams, the number to remember is the AED 10.4 billion listing value. Burjeel’s ADX outcome gave UAE hospital owners a public-market pricing reference after the collapse of NMC Health left investors more sensitive to governance, debt and related-party controls.

Why the $750 million report mattered

Arab News, citing Bloomberg, reported on 4 August 2022 that Burjeel Holdings was looking to raise $750 million in an IPO later that year. The figure put Burjeel in a higher category than small clinic transactions and pointed investors toward tertiary care, referral depth and Abu Dhabi’s insured patient base.

Burjeel Holdings then moved to a formal ADX process. Its IPO announcement on 30 September 2022 set the price range at AED 2.00 to AED 2.45 per share, implying an equity value of $2.7 billion to $3.3 billion. The subscription window ran from 30 September 2022 to 4 October 2022 for retail and professional investors.

• Offer stake: about 11% of issued share capital, equal to roughly 550.7 million shares.
• Listing venue: Abu Dhabi Securities Exchange main market.
• Regulatory approval: Securities and Commodities Authority approval on 23 September 2022.
• Final demand: more than AED 32.0 billion, equal to 29 times oversubscription.

What operators should read from ADX

Burjeel Holdings said its shares were priced at AED 2.00 when the listing completed on 10 October 2022, producing gross proceeds of more than AED 1.1 billion. Burjeel also said the final price implied a market capitalization of AED 10.4 billion, making it the largest healthcare company trading on ADX at listing.

For CFOs, the Burjeel benchmark was about margin, utilization and payer exposure, not bed count alone. Burjeel’s IPO materials described the group as a UAE private healthcare provider with about 17% inpatient market share, a figure that helps peers compare scale against claims collection, specialty mix and acute-care capacity.

The regulatory angle is direct for operators. Department of Health Abu Dhabi (DOH) licensing, claims oversight and quality standards shape Burjeel’s Abu Dhabi earnings base. Dubai Health Authority (DHA) rules affect Dubai expansion economics. Ministry of Health and Prevention (MOHAP) oversight applies to Northern Emirates facilities.

"A unique opportunity for investors to participate in an Abu Dhabi, UAE and MENA growth story." Dr. Shamsheer Vayalil, founder and chairman of Burjeel Holdings, in the company’s September 2022 intention-to-float statement

The takeaway for owners

Comparable UAE healthcare deals should now be judged against four Burjeel data points: the reported $750 million fundraising target, the 11% ADX offer, the AED 10.4 billion listing value and the 29 times oversubscription. Those figures give founders, private equity owners and hospital boards a sharper exit benchmark than revenue growth alone.

The Burjeel case also shows what public investors inspected. A credible UAE hospital exit needs clean DOH, DHA or MOHAP compliance records, audited growth, specific specialty capacity and payer data that can withstand public diligence. The professional takeaway is simple: the number to beat is AED 10.4 billion, and the competitor to watch is Burjeel Holdings.